Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS)

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease with high mortality. A 73-year-old woman presented to the hospital with fever after being bitten by ticks and was diagnosed with SFTS. Three days after treatment with high-flow oxygen and supportive therapy, her con...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Sai, Xu, Nannan, Wang, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798169/
https://www.ncbi.nlm.nih.gov/pubmed/36590553
http://dx.doi.org/10.1016/j.heliyon.2022.e12462
_version_ 1784860849117069312
author Wen, Sai
Xu, Nannan
Wang, Gang
author_facet Wen, Sai
Xu, Nannan
Wang, Gang
author_sort Wen, Sai
collection PubMed
description Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease with high mortality. A 73-year-old woman presented to the hospital with fever after being bitten by ticks and was diagnosed with SFTS. Three days after treatment with high-flow oxygen and supportive therapy, her condition deteriorated to septic shock and multiple organ failure. Ruxolitinib, a JAK1/2 inhibitor, was used for the treatment of cytokine release syndrome, and the patient finally recovered. Ruxolitinib and other host-based immunomodulatory drugs may be potential treatments for fatal SFTS.
format Online
Article
Text
id pubmed-9798169
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97981692022-12-30 Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS) Wen, Sai Xu, Nannan Wang, Gang Heliyon Case Report Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease with high mortality. A 73-year-old woman presented to the hospital with fever after being bitten by ticks and was diagnosed with SFTS. Three days after treatment with high-flow oxygen and supportive therapy, her condition deteriorated to septic shock and multiple organ failure. Ruxolitinib, a JAK1/2 inhibitor, was used for the treatment of cytokine release syndrome, and the patient finally recovered. Ruxolitinib and other host-based immunomodulatory drugs may be potential treatments for fatal SFTS. Elsevier 2022-12-19 /pmc/articles/PMC9798169/ /pubmed/36590553 http://dx.doi.org/10.1016/j.heliyon.2022.e12462 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Wen, Sai
Xu, Nannan
Wang, Gang
Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS)
title Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS)
title_full Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS)
title_fullStr Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS)
title_full_unstemmed Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS)
title_short Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS)
title_sort ruxolitinib for severe fever with thrombocytopenia syndrome (sfts)
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798169/
https://www.ncbi.nlm.nih.gov/pubmed/36590553
http://dx.doi.org/10.1016/j.heliyon.2022.e12462
work_keys_str_mv AT wensai ruxolitinibforseverefeverwiththrombocytopeniasyndromesfts
AT xunannan ruxolitinibforseverefeverwiththrombocytopeniasyndromesfts
AT wanggang ruxolitinibforseverefeverwiththrombocytopeniasyndromesfts

Ejemplares similares